CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.24 and traded as low as $0.20. CytoDyn shares last traded at $0.20, with a volume of 1,025,437 shares trading hands.
CytoDyn Price Performance
The firm’s fifty day moving average is $0.24 and its two-hundred day moving average is $0.18. The firm has a market cap of $251.42 million, a price-to-earnings ratio of -20.40 and a beta of 1.33.
About CytoDyn
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Recommended Stories
- Five stocks we like better than CytoDyn
- What is Forex and How Does it Work?
- Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally
- What Do S&P 500 Stocks Tell Investors About the Market?
- Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar
- How to Effectively Use the MarketBeat Ratings Screener
- Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
